SYBLEU (SYBE) Stock Analysis & Winston Score

SYBLEU Inc (ticker: SYBE) is a small biotechnology company in the healthcare sector. Biotech companies like this one typically focus on discovering and developing new drugs or medical treatments, often targeting diseases with few existing options. At this stage, SYBLEU appears to be an early-stage company without significant commercial products on the market.

SYBLEU generates little to no product revenue, which explains its 100% gross margin on minimal sales and its deeply negative operating margin — a common pattern for pre-revenue biotech firms that spend heavily on research while earning almost nothing yet. The company is very small, with a market cap near zero, suggesting it is in early development or facing financial stress. The central risk here is that early-stage biotechs frequently run out of cash before their drugs reach approval, and without a clear pipeline or partnership disclosed, investors face significant uncertainty about the company's path forward.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+0.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-11.8% YoY

YoY Growth Rate

Earnings declining

Insider Activity

71.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$176 cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

SYBLEU has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Operating Margin

-514.1%

Losing money on operations — -514.1%

ROCE

-15.4%

Weak — -15.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-728.2%

Burning cash (-728.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial